CN112121104B - 一种缓解视疲劳及防治近视的中药组合物 - Google Patents
一种缓解视疲劳及防治近视的中药组合物 Download PDFInfo
- Publication number
- CN112121104B CN112121104B CN202011246970.1A CN202011246970A CN112121104B CN 112121104 B CN112121104 B CN 112121104B CN 202011246970 A CN202011246970 A CN 202011246970A CN 112121104 B CN112121104 B CN 112121104B
- Authority
- CN
- China
- Prior art keywords
- parts
- fine powder
- traditional chinese
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 230000004379 myopia Effects 0.000 title claims abstract description 56
- 208000001491 myopia Diseases 0.000 title claims abstract description 56
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 27
- 239000004863 Frankincense Substances 0.000 claims abstract description 25
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 23
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 18
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 18
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 18
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 18
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 18
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 18
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 17
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 17
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 17
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 17
- 229940116229 borneol Drugs 0.000 claims abstract description 17
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 17
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 16
- JHGWQSGWUPCKNT-UHFFFAOYSA-N 2-tert-butyl-4-methyl-1,3,5-trinitrobenzene Chemical compound CC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C(C(C)(C)C)=C1[N+]([O-])=O JHGWQSGWUPCKNT-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 14
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims abstract description 14
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 14
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 14
- 235000006533 astragalus Nutrition 0.000 claims abstract description 14
- 235000008434 ginseng Nutrition 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 210000000582 semen Anatomy 0.000 claims abstract description 10
- 206010004542 Bezoar Diseases 0.000 claims abstract description 9
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 5
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 5
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 5
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 5
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 5
- 241000336291 Cistanche deserticola Species 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 59
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
- 238000002156 mixing Methods 0.000 claims description 39
- 239000000463 material Substances 0.000 claims description 26
- 241000005787 Cistanche Species 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 11
- 238000000227 grinding Methods 0.000 claims description 11
- 238000000643 oven drying Methods 0.000 claims description 11
- 238000005303 weighing Methods 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 30
- 230000008338 local blood flow Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 210000003205 muscle Anatomy 0.000 abstract description 4
- 210000001640 nerve ending Anatomy 0.000 abstract description 4
- 210000001328 optic nerve Anatomy 0.000 abstract description 4
- 206010013774 Dry eye Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 3
- 230000002411 adverse Effects 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 abstract description 2
- 230000004936 stimulating effect Effects 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000019606 astringent taste Nutrition 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 description 33
- 239000000243 solution Substances 0.000 description 21
- 239000003885 eye ointment Substances 0.000 description 16
- 230000004438 eyesight Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 12
- 240000004371 Panax ginseng Species 0.000 description 11
- 241001061264 Astragalus Species 0.000 description 9
- 210000004233 talus Anatomy 0.000 description 9
- 235000017784 Mespilus germanica Nutrition 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 244000182216 Mimusops elengi Species 0.000 description 8
- 235000000560 Mimusops elengi Nutrition 0.000 description 8
- 235000007837 Vangueria infausta Nutrition 0.000 description 8
- 229940099259 vaseline Drugs 0.000 description 8
- 241000717739 Boswellia sacra Species 0.000 description 7
- 244000153234 Hibiscus abelmoschus Species 0.000 description 7
- 241001057584 Myrrha Species 0.000 description 7
- 238000010298 pulverizing process Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 241000402754 Erythranthe moschata Species 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 5
- 210000005252 bulbus oculi Anatomy 0.000 description 5
- 235000013330 chicken meat Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000011049 pearl Substances 0.000 description 5
- 238000007873 sieving Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 229930003347 Atropine Natural products 0.000 description 3
- 244000037364 Cinnamomum aromaticum Species 0.000 description 3
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 3
- 244000293323 Cosmos caudatus Species 0.000 description 3
- 235000005956 Cosmos caudatus Nutrition 0.000 description 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000029091 Refraction disease Diseases 0.000 description 3
- 230000004430 ametropia Effects 0.000 description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 3
- 229960000396 atropine Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000036040 emmetropia Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000004402 high myopia Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000014733 refractive error Diseases 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010020675 Hypermetropia Diseases 0.000 description 2
- 208000006550 Mydriasis Diseases 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 230000004305 hyperopia Effects 0.000 description 2
- 201000006318 hyperopia Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004342 moderate myopia Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- 208000028048 Accommodation disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000003643 Callosities Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001517488 Clavus Species 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 244000272264 Saussurea lappa Species 0.000 description 1
- 235000006784 Saussurea lappa Nutrition 0.000 description 1
- 239000004830 Super Glue Substances 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000004323 axial length Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 210000004220 fundus oculi Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000011088 parchment paper Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004436 pseudomyopia Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/413—Gall bladder; Bile
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种缓解视疲劳及防治近视的纯中药组合物,原料药按重量份数计,包括:没药40‑45重量份、乳香40‑45重量份、人参8‑12重量份、枸杞子8‑12重量份、肉苁蓉8‑12重量份、柴胡8‑12重量份、黄芪3‑7重量份、菊花3‑7重量份、鸡血藤3‑7重量份、决明子3‑7重量份、人工牛黄1‑3重量份、人工麝香0.1‑1重量份、冰片0.1‑1重量份、薄荷1‑3重量份。该组合物可打眼部通经络、刺激神经末梢、促进局部血液循环,达到滋养肌肉和视神经,解除眼干、眼涩、眼疲劳等症状,标本兼治防治近视,无毒副作用;同时本发明还提供了所述缓解视疲劳及防治近视的纯中药组合物的剂型和制备方法,尤其是药膜剂,使治疗和使用方便,降低成本,操作简便,适于大规模生产。
Description
技术领域
本发明涉及一种中药组合物,具体涉及一种缓解视疲劳及防治近视的中药组合物,属于中药制剂领域。
背景技术
近视的发生与遗传、发育、环境等诸多因素有关。目前,信息化网络化已经融入人类的生活,人的视觉系统不得不接收更多的信息,眼睛长期处于疲劳状态,为了满足长时间的近距离阅读和精细操作,眼睛需要在近距离工作时进行长期适应性调节,导致近视的发生率大大增高。在中国青少年近视眼发病率已经达到60-80%,且每年仍在递增。近视眼已经成为视疲劳的主要病变之一,近视后的远视力可以通過凹透镜来矫正,通常用屈光度来衡量屈光不正的程度,0到-3.00D属于轻度近视,-3.00到-6.00D属于中度近视,高于-6.00D的则是高度近视。高度近视眼的人因为眼轴过长而属于一些眼病的高危人群,例如视网膜脱落、黄斑变性出血是致盲的重要因素。
国内外医疗工作者对近视眼的治疗进行了大量探索,目前已知的治疗方法主要有佩戴眼镜、使用光学矫正仪器、外科手术治疗、药物治疗(如使用阿托品)等,然而这些方法在治疗近视的过程中,都出现了各种不足,如不能根治近视,有副作用;手术治疗治标不治本且后遗并发症较多、物理疗法容易反复等缺陷
中医对本病早有认识,称为“目不能远视”,又名“能近怯远症”,至《目经大成》始称近视。由先天生成,近视程度较高者又称“近觑”。目失所养致使玄府受损而神光不能发越,看近清楚,看远不清是本病的证候特征。主症为:神光不足,视近清晰,视远模糊。次症有:视疲劳,眼球较突,眼偏斜,或眼底变性等。中医认为:近视眼由阳衰阴盛,经络气血涩滞所致。治宜扶阳抑阴,温补心脾肾阳气为主,兼以行气活血,养肝明目,则阴阳平衡,气血和畅,晶珠发光远近正常。中药治疗的原则就是清肝明目,常用的中药普遍都是具有清肝明目之效。最长见的治疗方法为内服外用,对近视具有一定的预防或者改善的作用。但是,众所周知,是药三分毒,对于内服的中草药而言,长期使用对人们的身体是具有副作用的。因此,如何同时达到治疗近视并最大限度降低中草药对人体的副作用,是目前本领域技术人员亟需解决的问题。
辽宁千里明药业(集团)有限公司的千里明眼膏的原料中使用了麝香、熊胆、牛黄、黄芪、珍珠、肉苁蓉等大量名贵中药材,成本高,导致价格较高。专利号为2003101102983的发明专利申请虽然相对减少了使用的药味和剂型,降低了成本,但仍然使用了较多的名贵药材,尤其像熊胆这样的中药材,不利于动物保护。
发明内容
本发明提供了一种缓解视疲劳及防治近视的纯中药组合物,可打眼部通经络、刺激神经末梢、促进局部血液循环,达到滋养肌肉和视神经,解除眼干、眼涩、眼疲劳等症状,标本兼治防治近视,无毒副作用;同时本发明还提供了所述缓解视疲劳及防治近视的纯中药组合物的剂型和制备方法,使治疗和使用方便,降低成本,操作简便,适于大规模生产。
本发明的一种缓解视疲劳及防治近视的中药组合物,原料药按重量份数计,包括:没药40-45重量份、乳香40-45重量份、人参8-12重量份、枸杞子8-12重量份、肉苁蓉8-12重量份、柴胡8-12重量份、黄芪3-7重量份、菊花3-7重量份、鸡血藤3-7重量份、决明子3-7重量份、人工牛黄1-3重量份、人工麝香0.1-1重量份、冰片0.1-1重量份、薄荷1-3重量份。
优选地,所述缓解视疲劳及防治近视的中药组合物的原料药按重量份数计,包括:没药42重量份、乳香42重量份、人参10重量份、枸杞子10重量份、肉苁蓉10重量份、柴胡10重量份、黄芪5重量份、菊花5重量份、鸡血藤5重量份、决明子5重量份、人工牛黄2.5重量份、人工麝香0.5重量份、冰片0.5重量份、薄荷2重量份。
所述中药组合物可以和医学上可以接受的辅料制成外用制剂。
所述外用制剂为眼药水、软膏剂、贴膏剂或药膜剂。
本发明的另一个目的在于,提供一种上述缓解视疲劳及防治近视的中药组合物的剂型及制备方法,使治疗和使用方便,降低成本,操作简便,适于大规模生产。
本发明的一种缓解视疲劳及防治近视的中药组合物的制备方法,包括的步骤如下:
按重量份称取各原料药,将没药、乳香、人工牛黄、人工麝香、冰片、薄荷粉碎成细粉;其余中药材加乙醇溶液提取,提取液滤过,合并滤液,回收乙醇,浓缩成浸膏,烘干,研成细粉,合并上述药材细粉与浸膏细粉,混匀,制成混合细粉,加入常规辅料制成外用制剂。
进一步地,包括的步骤如下:
按重量份称取各原料药,将没药、乳香、人工牛黄、人工麝香、冰片、薄荷粉碎成细粉;其余中药材加40%乙醇溶液提取两次,第一次加8倍量乙醇溶液,提取1.5小时,第二次加8倍量乙醇溶液,提取1小时,滤过,合并滤液,回收乙醇,加压浓缩至在60-70℃时相对密度为1.30-1.32的浸膏,烘干,研成细粉,合并上述药材细粉与浸膏细粉,混匀,制成混合细粉,加入常规辅料制成外用制剂。
进一步地,向所述混合细粉加入适量丙烯酸树脂15kg、柠檬酸三乙酯1.3kg,用体积比1∶1的乙醇与丙酮的混合液25升浸泡,常温溶解后制成黄色粘稠液体,再用涂布机转移涂布,经60℃干燥,盖上防粘层,切割即得药膜剂。
本发明的中药组合物所用的中药材为正规市售中药材,辅料为药用辅料,均符合相关标准的规定。其中没药散血祛瘀、消肿定痛,乳香活血止痛、消肿生肌,二者共为君药,可打眼部通经络、促进局部血液循环;人参大补元气,枸杞子滋肾阴明目,肉苁蓉补肾阳益精血,柴胡疏肝利胆,上述四味共为臣药,滋补肝肾,升阳益气;黄芪、菊花、鸡血藤、决明子、人工牛黄为佐药,进一步增强益气血,清热明目;人工麝香、冰片、薄荷开窍通络,助药物成分吸收及药效发挥。上述诸药相互配合,共同达到通眼部经络、促进局部血液循环、刺激神经末梢、滋养肌肉和视神经、解除眼干、眼涩、眼疲劳等症状,标本兼治防治近视的作用,且不产生治疗反复、无毒副作用。
本发明的产品和制备方法的有益效果是:
1)本发明缓解视疲劳及防治近视的中药组合物使用的名贵药味进一步减少,有效率和治愈率好,药物成本低,有利于患者的治疗和使用。
2)本发明缓解视疲劳及防治近视的中药组合物可打眼部通经络、刺激神经末梢、促进局部血液循环,以达到滋养肌肉和视神经,标本兼治治疗近视眼的目的,而不产生治疗反复、无毒副作用。
3)本发明的剂型能够进一步减少中药材本身的不良作用,安全有效,携带及使用方便。
4)本发明的制备方法,工艺简单,有利于大规模生产。
四、具体实施方式
以下用具体的实施例将有助于进一步说明对本发明,实施例对本发明的保护范围没有限定。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规产品。
实施例1
称取没药42g、乳香42g、人参10g、枸杞子10g、肉苁蓉10g、柴胡10g、黄芪5g、菊花5g、鸡血藤5g、决明子5g、人工牛黄2.5g、人工麝香0.5g、冰片0.5g、薄荷2g。将没药、乳香、人工牛黄、人工麝香、冰片、薄荷粉碎成细粉;其余中药材加乙醇溶液提取,提取液滤过,合并滤液,回收乙醇,浓缩成浸膏,烘干,研成细粉,合并上述药材极细粉与浸膏极细粉,混匀,制成混合细粉,与1kg加热消毒除杂后降温至60℃的凡士林混匀,即得眼膏剂。
实施例2
称取没药42g、乳香42g、人参10g、枸杞子10g、肉苁蓉10g、柴胡10g、黄芪5g、菊花5g、鸡血藤5g、决明子5g、人工牛黄2.5g、人工麝香0.5g、冰片0.5g、薄荷2g。将没药、乳香、人工牛黄、人工麝香、冰片、薄荷粉碎成极细粉;其余中药材加乙醇溶液提取,提取液滤过,合并滤液,回收乙醇,浓缩成浸膏,烘干,研成细粉,合并上述药材极细粉与浸膏极细粉,混匀,制成混合细粉,向所述混合细粉加入适量丙烯酸树脂15kg、柠檬酸三乙酯1.3kg,用体积比1∶1的乙醇与丙酮的混合液25升浸泡,常温溶解后制成黄色粘稠液体,再用涂布机转移涂布,经60℃干燥,盖上防粘层,切割即得药膜剂。
实施例3
称取没药40g、乳香45g、人参8g、枸杞子12g、肉苁蓉8g、柴胡12g、黄芪6g、菊花3g、鸡血藤7g、决明子7g、人工牛黄1g、人工麝香0.2g、冰片0.6g、薄荷3g。将没药、乳香、人工牛黄、人工麝香、冰片、薄荷粉碎成极细粉;其余中药材加乙醇溶液提取,提取液滤过,合并滤液,回收乙醇,浓缩成浸膏,烘干,研成细粉,合并上述药材细粉与浸膏细粉,混匀,制成混合细粉,过筛,与1kg加热消毒除杂后降温至60℃的凡士林混匀,即得眼膏剂。
为了降低本发明中药组合物的成本的同时还能保证效果,发明人进行了大量对药物的组成及其药效的动物实验验证和临床实验考察。以下仅列举部分最相关的中药组合物及对比实验结果用以说明本发明中药组合物的有益效果。
对比例1
称取没药42g、乳香42g、人参10g、枸杞子10g、肉苁蓉10g、柴胡10g、黄芪5g、菊花5g、鸡血藤5g、决明子5g、珍珠4g、人工牛黄2.5g、人工麝香0.5g、冰片0.5g、薄荷2g。将没药、乳香、珍珠、人工牛黄、人工麝香、冰片、薄荷粉碎成细粉;其余中药材加乙醇溶液提取,提取液滤过,合并滤液,回收乙醇,浓缩成浸膏,烘干,研成细粉,合并上述药材极细粉与浸膏细粉,混匀,制成混合细粉,过筛,与1kg加热消毒除杂后降温至60℃的凡士林混匀,即得眼膏剂。
对比例2
称取没药42g、乳香42g、人参10g、枸杞子10g、肉苁蓉10g、柴胡10g、黄芪5g、菊花5g、鸡血藤5g、决明子5g、珍珠4g、人工麝香0.5g、冰片0.5g、薄荷2g。将没药、乳香、珍珠、人工麝香、冰片、薄荷粉碎成细粉;其余中药材加乙醇溶液提取,提取液滤过,合并滤液,回收乙醇,浓缩成浸膏,烘干,研成细粉,合并上述药材细粉与浸膏细粉,混匀,制成混合细粉,过筛,与1kg加热消毒除杂后降温至60℃的凡士林混匀,即得眼膏剂。
对比例3
称取没药42g、乳香42g、人参10g、枸杞子10g、肉苁蓉10g、柴胡10g、黄芪5g、菊花5g、丹参5g、决明子5g、人工牛黄2.5g、人工麝香0.5g、冰片0.5g、薄荷2g。将没药、乳香、人工牛黄、人工麝香、冰片、薄荷粉碎成细粉;其余中药材加乙醇溶液提取,提取液滤过,合并滤液,回收乙醇,浓缩成浸膏,烘干,研成细粉,合并上述药材细粉与浸膏细粉,混匀,制成混合细粉,过筛,与1kg加热消毒除杂后降温至60℃的凡士林混匀,即得眼膏剂。
对比例4
称取没药20g、乳香20g、人参15g、肉苁蓉20g、木香15g、黄芪27g、菊花23g、珍珠7.5g、熊胆粉1.5g、人工麝香0.5g。将没药、乳香、珍珠、人工麝香、熊胆粉粉碎成细粉;其余中药材加乙醇溶液提取,提取液滤过,合并滤液,回收乙醇,浓缩成浸膏,烘干,研成细粉,合并上述药材细粉与浸膏细粉,混匀,制成混合细粉,过筛,与1kg加热消毒除杂后降温至60℃的凡士林混匀,即得眼膏剂。
试验例1 皮肤急性毒性试验:
试验方法:选用成年健康豚鼠6只,体重350-450g,雌雄各半。于给药前24h将豚鼠背部脊柱两侧脱毛。试验时剪取本申请实施例2制备的药膜剂作为受试药物,均匀涂擦在豚鼠背部脱毛区(范围约20cm2),用两层硫酸纸覆盖,用无刺激性胶布封闭固定24h,24h后去除受试物,观察动物中毒体征,观察期7天,试验结束处死动物并观察人体病理改变。
试验结果:试验动物均未出现中毒体征,观察期无动物死亡,病理解剖学检查未见异常。
结论:受试药物对豚鼠皮肤无毒。
试验例2 急性眼刺激性试验:
试验方法:选用成年健康家兔3只,体重2.0-3.0kg,试验时将本申请实施例1制备的眼膏作为受试药物,涂抹于家兔右侧眼周,另一侧眼睛作自身对照。滴入受试物后1h、24h、48h、72h及第4天和第7天,观察受试侧眼刺激反应情况。
实验结果:涂抹受试药物后,各时间点受试侧眼均未出现刺激反应,动物的角膜、虹膜无损害,结膜无充血水肿积分。
结论:受试药物对家兔眼无刺激性。
实验例3
对形觉剥夺近视小鸡眼的影响
试验方法:采用孵出后2天的健康普通家鸡48只,分为8组,每组6只,除正常组外,其余各组用强力胶将圆形半透明眼罩固定于鸡右眼鼻侧,以遮盖侧视野;左眼不戴眼罩,作对照眼;依据组别每天早、晚右眼周涂抹凡士林或药物2次(实验组1给予本发明实施例1制备的眼膏,实验组2给予本发明实施例3制备的眼膏,对照组1-4分别给予本发明对比例1-4制备的眼膏),室内饲养,室温28-32℃,采用人工照明,昼夜12h循环。五周后,麻醉处死,取鸡头浸入固定液固定24h,摘出眼球,称重,测量眼球的视轴、鼻颞赤道径和腹背赤道径的长度。
表1 对形觉剥夺近视小鸡眼的影响
与凡士林组比较 * p<0.05;** p<0.01
实验结果:遮盖眼与正常眼比较,呈明显的近视状态,说明造模成功。各实验组和对照组均有防治眼球增重、减少视轴、鼻颞赤道径和腹背赤道径的延长的效果。其中实验组1和对照1组效果最好,其次是实验组2。后续经不同组别差值的多重比较发现,实验组1、2和对照组1之间没有显著差别,说明原料中增加珍珠对疗效影响不大,实验组1的配比和用量最佳,更换原料药或改变用量都有可能降低中药组合物的效果。经筛选,在没药40-45g、乳香40-45g、人参8-12g、枸杞子8-12g、肉苁蓉8-12g、柴胡8-12g、黄芪3-7g、菊花3-7g、鸡血藤3-7g、决明子3-7g、人工牛黄1-3g、人工麝香0.1-1g、冰片0.1-1g、薄荷1-3g的范围内的中药组合物均具有较好的效果。
实验例4 临床资料
1)病例来源
收集2018年7月至2019年12月份来自营口市某院眼科患者180例。
2)诊断标准及分类
诊断标准参考《中华眼科学》中近视的诊断及分类标准拟定。近视诊断标准为眼在调节松弛的状态下,平行光线经眼的屈光系统后,在视网膜前形成焦点,远点移近,屈光力大于眼球轴长的一种屈光不正。
根据近视程度分类:
①轻度近视眼:<-3.0D的近视;
②中度近视眼:-3.0D~-6.0D的近视;
③高度近视眼:>-6.0D的近视。
根据调节作用参与分类:
①假性近视眼:由于调节痉挛,使正视眼或远视眼表现出一时性近视现象。用,阿托品散瞳后检查,近视消失呈现为正视或远视;
②真性近视眼:用药后屈光度未降低或降低度数<-0.50D;
③混合性近视眼:用药后屈光度降低≥-0.50D,但未恢复正视者;
排除标准:
①与上述诊断及纳入标准不匹配者;
②患者合并它眼病,对疗效判定有影响者;
③患者有心、脑血管等全身性疾病及精神病患者;
④正在进行其它治疗方法者。
3)分组与治疗方法
将纳入的180例患者,根据门诊就诊的先后顺序,随机分成3组,治疗过程中脱落7例。其余参与并完成本研究的患者共计173例,其中治疗1组58例,治疗2组59例,对照组56例。治疗1组给予本发明实施例1制备的眼膏,治疗2组给予本发明实施例2制备的药膜,对照组给予市售千里明眼膏,一天一次,2个月后行各项观察指标检测。
4)观察指标
①远视力 被治疗者在治疗前后均需查标准对数视力表,站在据灯箱5米标线处,先查右眼,后查左眼,从上至下依次检查;
②屈光度 用阿托品滴眼液散瞳后用综合验光仪先做客观验光,再做主观验光。等五天瞳孔恢复以后,再做复验;
③眼轴长度 使用眼科A超仪(CINESCAN)测量眼轴,自动测量10次,取平均值。
5)疗效标准 采用标准对数视力表对视力的划分方法:
痊愈:视力达到正常水平;
显效:视力提高5行以上;
有效:视力提高l行~4行;
无效:治疗后视力较前不变,或下降,或提高不足l行。
6)统计方法
采用SPSS17.0软件进行数据处理,各组内治疗的前后计量资料,采用配对t检验,用(±s)进行统计描述,三组间比较采用方差分析,若方差齐采用独立样本t检验,方差不齐采用秩和检验,计数资料两组比较采用检验。患者的一般资料采用(±s)定量统计描述,检验水准α=0.05,p<0.05则差异具有统计学意义。
7)治疗结果
经方差分析,三组患者治疗前各项检查组间比较结果差异无统计学意义,说明三组患者治疗前在屈光度、远视力及眼轴长度方面均无明显差异,资料具有可比性。
三组患者在治疗后各项检查结果与治疗前绝对差值比较如下表:
表2 各组患者远视力、屈光度、眼轴长度治疗前后差值比较
实验结果表明,治疗1组、治疗2组和对照组的治疗均可改善屈光不正,对远视力及屈光度疗效显著,但各组治疗方法对眼轴长度的影响不是特别明显。
表3 各组患者总有效率比较
实验结果表明,治疗1组、治疗2组和对照组对于提高近视患者视力均有明显疗效,且治疗2组优于治疗1组和对照组,可能主要是使用的辅料及剂型的原因。
本发明缓解视疲劳及防治近视的中药组合物的配伍经过了大量实验,各原料药之间相互配合,能够取得最佳的效果,其中任何原料药的替换都有可能导致效果的降低。本发明缓解视疲劳及防治近视的中药组合物所使用的原料药与现有技术千里明眼膏相比,名贵药味少,尤其没有使用不利于动物保护的熊胆粉等,降低了生产成本,但治疗效果不低于甚至还高于千里明眼膏。其中,本发明缓解视疲劳及防治近视的中药组合物的药膜剂具有效果更好的有益效果。
本发明实施例仅是为清楚地说明所作的举例,而并非对实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
Claims (6)
1.一种缓解视疲劳及防治近视的中药组合物,其特征在于:所述中药组合物的原料药按重量份数计:没药40-45重量份、乳香40-45重量份、人参8-12重量份、枸杞子8-12重量份、肉苁蓉8-12重量份、柴胡8-12重量份、黄芪3-7重量份、菊花3-7重量份、鸡血藤3-7重量份、决明子3-7重量份、人工牛黄1-3重量份、人工麝香0.1-1重量份、冰片0.1-1重量份、薄荷1-3重量份。
2.根据权利要求1的缓解视疲劳及防治近视的中药组合物,所述中药组合物的原料药按重量份数计:没药42重量份、乳香42重量份、人参10重量份、枸杞子10重量份、肉苁蓉10重量份、柴胡10重量份、黄芪5重量份、菊花5重量份、鸡血藤5重量份、决明子5重量份、人工牛黄2.5重量份、人工麝香0.5重量份、冰片0.5重量份、薄荷2重量份。
3.根据权利要求1或2的缓解视疲劳及防治近视的中药组合物,其特征在于:所述中药组合物的制剂为外用制剂。
4.根据权利要求3的缓解视疲劳及防治近视的中药组合物,其特征在于:所述外用制剂为软膏剂、贴膏剂或药膜剂。
5.根据权利要求1或2的缓解视疲劳及防治近视的中药组合物的制备方法,其特征在于,包括的步骤如下:按重量份称取各原料药,将没药、乳香、人工牛黄、人工麝香、冰片、薄荷粉碎成细粉;其余中药材加乙醇溶液提取,提取液滤过,合并滤液,回收乙醇,浓缩成浸膏,烘干,研成细粉,合并上述药材细粉与浸膏细粉,混匀,制成混合细粉,加入常规辅料制成外用制剂。
6.根据权利要求1或2的缓解视疲劳及防治近视的中药组合物的制备方法,其特征在于,包括的步骤如下:按重量份称取各原料药,将没药、乳香、人工牛黄、人工麝香、冰片、薄荷粉碎成细粉;其余中药材加40%乙醇溶液提取两次,第一次加8倍量乙醇溶液,提取1.5小时,第二次加8倍量乙醇溶液,提取1小时,滤过,合并滤液,回收乙醇,浓缩至在60-70℃时相对密度为1.30-1.32的浸膏,烘干,研成细粉,合并上述药材细粉与浸膏细粉,混匀,制成混合细粉,加入常规辅料制成外用制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011246970.1A CN112121104B (zh) | 2020-11-10 | 2020-11-10 | 一种缓解视疲劳及防治近视的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011246970.1A CN112121104B (zh) | 2020-11-10 | 2020-11-10 | 一种缓解视疲劳及防治近视的中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112121104A CN112121104A (zh) | 2020-12-25 |
CN112121104B true CN112121104B (zh) | 2021-11-09 |
Family
ID=73851958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011246970.1A Active CN112121104B (zh) | 2020-11-10 | 2020-11-10 | 一种缓解视疲劳及防治近视的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112121104B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114028479A (zh) * | 2021-11-29 | 2022-02-11 | 浙江百越生物技术有限公司 | 一种可以缓解眼部疲劳及氧化损伤的组合物 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1528434A (zh) * | 2003-12-31 | 2004-09-15 | 林继华 | 一种治疗近视眼的中药组合物及制法 |
CN101642511A (zh) * | 2009-09-07 | 2010-02-10 | 林继华 | 一种缓解视疲劳治疗假性近视的中药组合物及其制备方法 |
CN105521156A (zh) * | 2015-12-30 | 2016-04-27 | 钱蕊丹 | 一种缓解眼部疲劳的按摩药水 |
CN105920267A (zh) * | 2016-05-23 | 2016-09-07 | 辽宁千里明药业(集团)有限公司 | 一种治疗近视的中药组合物 |
EP3130336A1 (en) * | 2015-08-11 | 2017-02-15 | Graal S.r.l. | Food and/or nutraceutical composition containing pea |
CN111214583A (zh) * | 2018-11-27 | 2020-06-02 | 广西小咕噜生物科技有限公司 | 一种具有缓解视疲劳的护眼药包 |
-
2020
- 2020-11-10 CN CN202011246970.1A patent/CN112121104B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1528434A (zh) * | 2003-12-31 | 2004-09-15 | 林继华 | 一种治疗近视眼的中药组合物及制法 |
JP2005194276A (ja) * | 2003-12-31 | 2005-07-21 | Keika Rin | 近視を治療するための漢方薬組成物及びその製造方法 |
CN101642511A (zh) * | 2009-09-07 | 2010-02-10 | 林继华 | 一种缓解视疲劳治疗假性近视的中药组合物及其制备方法 |
EP3130336A1 (en) * | 2015-08-11 | 2017-02-15 | Graal S.r.l. | Food and/or nutraceutical composition containing pea |
CN105521156A (zh) * | 2015-12-30 | 2016-04-27 | 钱蕊丹 | 一种缓解眼部疲劳的按摩药水 |
CN105920267A (zh) * | 2016-05-23 | 2016-09-07 | 辽宁千里明药业(集团)有限公司 | 一种治疗近视的中药组合物 |
CN111214583A (zh) * | 2018-11-27 | 2020-06-02 | 广西小咕噜生物科技有限公司 | 一种具有缓解视疲劳的护眼药包 |
Non-Patent Citations (2)
Title |
---|
中药离子导入治疗大龄儿童弱视疗效观察;王忻;《现代中西医结合杂志》;20101110;第19卷(第32期);4161-4162 * |
中药离子导入配合穴位按摩对儿童弱视的图形视觉诱发电位的影响;何碧华等;《广西医学》;20130315;第35卷(第03期);298-300 * |
Also Published As
Publication number | Publication date |
---|---|
CN112121104A (zh) | 2020-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102145126B (zh) | 治疗干眼症的药物组合物 | |
CN104784270B (zh) | 一种消肿止痛外用制剂及其制备方法 | |
CN108578523A (zh) | 防治黄斑变性白内障近视的气化渗透脂眼镜及其制备方法 | |
CN112121104B (zh) | 一种缓解视疲劳及防治近视的中药组合物 | |
CN112138046A (zh) | 一种治疗干眼症、视疲劳的药物组合物及其制备方法和用途 | |
CN104435541A (zh) | 一种用于治疗近视的膏药及其制备方法 | |
CN115645454A (zh) | 一种治疗近视的外用乳膏及其制备方法 | |
CN105326954B (zh) | 一种治疗睑缘炎的中药组合物及其制备方法 | |
CN104306546B (zh) | 一种用于治疗视神经萎缩的中药组合物及其汤剂、丸剂和散剂 | |
CN116211984B (zh) | 一种防治儿童青少年近视的中药组合物眼膏及其制备方法 | |
CN107029037A (zh) | 一种基于一氧化氮原理改善眼睛的明目保健贴 | |
CN116115722B (zh) | 一种防治儿童和青少年远视的中药眼膏及其制备方法 | |
CN113082164A (zh) | 一种缓解近视的中药组合物及其应用 | |
CN112294963A (zh) | 一种治疗年龄相关性黄斑变性的药物组合物 | |
CN117883524B (zh) | 一种养肝明目组合物及其制备方法和应用 | |
CN104096153A (zh) | 一种包含多种植物活性成分的药物组合物及其制备方法和用途 | |
CN108498615A (zh) | 一种基于一氧化氮原理改善眼睛的中药眼保健贴及其制备方法 | |
CN103751358B (zh) | 一种用于矫治屈光不正眼疾的中药组合物 | |
CN116983339A (zh) | 一种防治青少年气滞血瘀证近视的外用中药组合物及其应用 | |
CN100500192C (zh) | 治疗眼睛玻璃体积血、浑浊的药物及其制备方法 | |
CN106491730A (zh) | 一种治疗青光眼的中药组合物及其制备方法 | |
CN115737725A (zh) | 一种治疗干眼症的中药组合物及其制备方法 | |
CN115381885A (zh) | 一种用于治疗或缓解视疲劳或视频综合症的中药组合物 | |
CN113304217A (zh) | 一种用于治疗2型糖尿病性干眼和过敏性睑皮炎的中药熏眼制剂及其制备方法 | |
Seo | SOUTH BAYLO UNIVERSITY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |